阿里健康(00241.HK)戰略投資醫療大數據平台零氪科技
內媒報道,阿里健康(00241.HK)近日完成戰略投資醫療大數據平台零氪科技,預期雙方將共同建設中國腫瘤患者全疾病週期服務平台,探索線上腫瘤專科藥品創新服務模式,但未有披露投資金額。
零氪科技表示,本輪融資後零氪互聯網醫院及腫瘤患者服務中心將連接阿里健康平台,未來會根據在腫瘤垂直領域積累的數據治理、輔助診療、科研服務、患者管理、醫生運營、藥品發行等優勢,以患者為中心來開展線上線下各類資源的銜接,建立服務閉環。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.